ProQR Therapeutics N.V.

NasdaqCM:PRQR 株式レポート

時価総額:US$384.9m

ProQR Therapeutics 過去の業績

過去 基準チェック /06

ProQR Therapeuticsは6.2%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで19%毎年増加している。売上は成長しており、年平均38.8%の割合である。

主要情報

6.2%

収益成長率

21.2%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率38.8%
株主資本利益率-64.7%
ネット・マージン-136.6%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump

Oct 23
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump

ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Jul 15
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

May 29
Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Apr 03
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Nov 28
Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Jul 30
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Mar 17
Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

ProQR says EU regulator seeks additional trial for lead candidate

Aug 11

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Nov 10
Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Investment Case On ProQR Therapeutics Gets More Enticing

Oct 01

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Aug 04
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

Jun 20

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

May 13
It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

ProQR Therapeutics offers a de-risked opportunity: Stifel

May 03

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Mar 08
If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

Feb 01
Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder

Jan 07

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Dec 28
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Dec 01
A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

収支内訳

ProQR Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:PRQR 収益、費用、利益 ( )EUR Millions
日付収益収益G+A経費研究開発費
30 Jun 2416-221530
31 Mar 2411-271628
31 Dec 237-281625
30 Sep 235-371428
30 Jun 234-541738
31 Mar 234-591844
31 Dec 224-641951
30 Sep 224-692153
30 Jun 224-612048
31 Mar 223-631947
31 Dec 212-611742
30 Sep 212-571638
30 Jun 212-551435
31 Mar 211-431334
31 Dec 201-471438
30 Sep 201-521444
30 Jun 201-511446
31 Mar 202-581447
31 Dec 192-561346
30 Sep 193-511442
30 Jun 195-451337
31 Mar 196-401334
31 Dec 186-371330
30 Sep 184-351128
30 Jun 182-401129
31 Mar 181-441131
31 Dec 171-441131
30 Sep 171-411031
30 Jun 171-41932
31 Mar 171-39933
31 Dec 162-39932
30 Sep 163-36930
30 Jun 163-33928
31 Mar 163-31825
31 Dec 153-21723
30 Sep 153-17720
30 Jun 151-14817
31 Mar 151-10814
31 Dec 140-12710
30 Sep 140-1258
30 Jun 140-936
31 Mar 140-514
31 Dec 130-313

質の高い収益: PRQRは現在利益が出ていません。

利益率の向上: PRQRは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: PRQRは利益を出していないが、過去 5 年間で年間6.2%の割合で損失を削減してきた。

成長の加速: PRQRの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: PRQRは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -2.3% ) と比較することは困難です。


株主資本利益率

高いROE: PRQRは現在利益が出ていないため、自己資本利益率 ( -64.69% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘